AbbVie will present new research on the efficacy, durability and safety of RINVOQ (upadacitinib) and SKYRIZI (risankizumab-rzaa). Notable data will include a post-hoc analysis from the Heads Up study evaluating the degree and distribution of skin improvement from baseline with RINVOQ versus DUPIXENT (dupilumab) in adults with moderate to severe atopic dermatitis. Additionally, AbbVie will present an interim analysis from the LIMMitless open-label extension trial investigating continuous SKYRIZI treatment beyond 4.5 years in adults with moderate to severe plaque psoriasis, as well as new real-world findings from the CorEvitas Psoriasis Registry, including patient reported outcomes with SKYRIZI in adults with moderate to severe plaque psoriasis.
'We look forward to presenting data at AAD that demonstrate our leadership in and commitment to advancing research across a myriad of dermatologic conditions,' said
Allergan Aesthetics has one of the most researched portfolios in the aesthetics industry and will spotlight a novel hydrating serum. Additionally, the company will share results from a multicenter and randomized controlled study evaluating the safety and effectiveness of hyaluronic acid (HA) injectable gel for restoring jawline definition as well as data on the effectiveness and safety of onabotulinumtoxinA for the treatment of masseter muscle prominence.
'Our research and development team is focused on driving innovation to provide the most comprehensive, science-based product offerings that will continue to help advance aesthetic medicine,' said
About RINVOQ (upadacitinib)
Discovered and developed by AbbVie scientists, RINVOQ is a selective JAK inhibitor that is being studied in several immune-mediated inflammatory diseases.1 Based on enzymatic and cellular assays, RINVOQ demonstrated greater inhibitory potency for JAK-1 vs JAK-2, JAK-3, and TYK-2.2 The relevance of inhibition of specific JAK enzymes to therapeutic effectiveness and safety is not currently known.
In the
Phase 3 trials of RINVOQ in rheumatoid arthritis, atopic dermatitis, psoriatic arthritis, axial spondyloarthritis, Crohn's disease, ulcerative colitis, giant cell arteritis and Takayasu arteritis are ongoing.3-10
About AbbVie
AbbVie's mission is to discover and deliver innovative medicines that solve serious health issues today and address the medical challenges of tomorrow. We strive to have a remarkable impact on people's lives across several key therapeutic areas: immunology, oncology, neuroscience, eye care, virology, women's health and gastroenterology, in addition to products and services across its Allergan Aesthetics portfolio. For more information about AbbVie, please visit us at www.abbvie.com. Follow @abbvie on Twitter, Facebook, LinkedIn or Instagram.
About Allergan Aesthetics
Allergan Aesthetics, an AbbVie company, develops, manufactures, and markets a portfolio of leading aesthetics brands and products. Their aesthetics portfolio includes facial injectables, body contouring, plastics, skin care, and more. Their goal is to consistently provide customers worldwide with innovation, education, exceptional service, and a commitment to excellence, all with a personal touch. www.AllerganAesthetics.com
AbbVie Forward-Looking Statements
Some statements in this news release are, or may be considered, forward-looking statements for purposes of the Private Securities Litigation Reform Act of 1995. The words 'believe,' 'expect,' 'anticipate,' 'project' and similar expressions, among others, generally identify forward-looking statements. AbbVie cautions that these forward-looking statements are subject to risks and uncertainties that may cause actual results to differ materially from those indicated in the forward-looking statements. Such risks and uncertainties include, but are not limited to, failure to realize the expected benefits from AbbVie's acquisition of
Contact:
AbbVie US Media
T: +1 (224) 214-8638
E: Stephanie.Tennessen@abbvie.com
(C) 2022 Electronic News Publishing, source